Multicenter, prospective, randomized, double-blind, placebo-controlled study to evaluate the effect of diacerein to prevent death or dysfunction of organic organs in patients with ARDS secondary to COVID-19

• Grant number: 20/12649-5
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• Start date: November 01, 2020
• End date: June 30, 2022
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Andrei Carvalho Sposito
• Grantee: Alejandro Rosell Castillo
• Host Institution: Faculdade de Ciências Médicas (FCM). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil
• Associated research grant: 20/05430-7 - Multicenter, prospective, randomized, double-blind, placebo-controlled study to evaluate the Effect of Diacerein to prevent death or multiple organ dysfunction in patients with ARDS secondary to COVID-19, AP.R

Abstract

Since its report by the World Health Organization in February 2020, SARS-CoV-2 has spread rapidly at an alarming rate, becoming a pandemic on March 12, 2020. In early April, more than 1 million cases were reported. confirmed and there are no signs of slowdown in transmission. Brazil, with more than 10,000 cases as of the beginning of April 2020, is the most affected country in Latin America and its daily growth of confirmed cases is on an equal footing with the rest of the world. Pyroptosis is an inflammatory form of programmed cell death that occurs most frequently after infection by intracellular pathogens and has been described as occurring in severe coronavirus infections caused by SARS-CoV, MERS-CoV and SARS-CoV-2. Through a direct effect of viral capsule proteins such as viroporin 3a, the NLRP3 inflammasome is activated generating damage and rupture of the cell membrane. This process is further intensified with the activation of caspase-1 and the production of gasdermin D and interleukin 1B; (IL1B). In addition, cell death results in the release of DAMPs in neighboring cells and subsequent activation of the NLRP3 inflammasome, thus propagating the extent of the damage. In this context, reaching the inflammatory cascade and pyroptosis is potentially a viable way to control host injury in cases of severe COVID-19. Diacerein and its active metabolite, the reign, decreases the production of IL-1B AND cell death by pyroptosis by inhibiting caspase-1 E can also inhibit IL-6 production. The attenuation of the production of these inflammatory cytokines has the potential to decrease the severity of the disease, especially in those who are hospitalized with COVID-19. In cell models, the inflammatory response to IL-1B is completely reversed with diacerein treatment. In a rat model of acute sepsis-induced inflammation, diacerein reduced caspase activity and kappa nuclear factor B. Currently, there are no studies on the effect of diacerein on the acute inflammatory response in humans. However, when extrapolating human and in vitro animal model data for patients with severe manifestations of COVID-19, it can be postulated that the attenuation of pyroptosis and inflammatory activation may be a clinical benefit for these patients. Diacerein has been on the market for approximately 20 years and has been approved for use in osteoarthritis and other inflammatory conditions such as Epidermolysis Bullosa. It is accessible and well tolerated by patients with rare cases of gastrointestinal disorder. For this, 300 patients will be enrolled in a double-blind, randomized, placebo-controlled study in which diacerein treatment will be tested. The primary outcome will be time to clinical worsening, defined as the time from randomization to mortality or worsening of the World Health Organization (WHO) progression scale. Secondary and tertiary outcomes will be aimed at understanding disease mechanisms and investigating risk predictors.

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

CARMO, HELISON RAFAEL P.; YOSHINAGA, MARCOS Y.; CASTILLO, ALEJANDRO ROSELL; CHAVES-FILHO, ADRIANO BRITTO; BONILHA, ISABELLA; BARRETO, JOAQUIM; MURARO, STEFANIE PRIMON; DE SOUZA, GABRIELA FABIANO; DAVANZO, GUSTAVO GASTAO; PERROUD JR, MAURICIO W.; et al. Phenotypic changes in low-density lipoprotein particles as markers of adverse clinical outcomes in COVID-19. MOLECULAR GENETICS AND METABOLISM, v. 138, n. 4, p. 8-pg., 2023-03-06. (20/04558-0, 20/12649-5, 16/00194-8, 13/07937-8, 18/17792-0)